News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Philogen S.p.A. IPO Pulled as Bayer Corporation Exits Cancer Pact
February 15, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- An eagerly-anticipated initial public offering by the Swiss-Italian biotech Philogen has been cancelled at the last minute after partner Bayer pulled out of their oncology collaboration.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Bayer
MORE ON THIS TOPIC
Mergers & acquisitions
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
April 3, 2026
·
3 min read
·
Annalee Armstrong
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
March 31, 2026
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
March 31, 2026
·
2 min read
·
Tristan Manalac
